Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 400-408

  Tsunoda, Fumiyoshi ^a   Lamon Fava, Stefania ^a   Asztalos, Bela F ^a   Iyer, Lakshmanan K ^b,c   Richardson, Kris ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Gene expression; Hypoxia inducible factor 1; Microarray analysis; Peripheral blood mononuclear cells; subunit

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE RECEPTOR ANTAGONIST; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ICOSAPENTAENOIC ACID; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 2 RECEPTOR BETA; LIPOPROTEIN; OLIVE OIL; PATTERN RECOGNITION RECEPTOR; PHOSPHOLIPASE A2; S ADENOSYLMETHIONINE; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; PLA2G7 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOSYNTHESIS; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLYCOLYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SHUNTING; SIGNAL TRANSDUCTION; BLOOD; COMPARATIVE STUDY; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MASSACHUSETTS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME FACTOR; UPREGULATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADMINISTRATION, ORAL; ADULT; BIOMARKERS; BOSTON; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIVE OIL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84936804810     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.015     Document Type: Article

References (46)

1. Marik P.E., Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin. Cardiol. 2009, 32(7):365-372.
2. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006, 83(6 Suppl. l):1505s-1519s.
3. Hansson G.K. Inflammation, atherosclerosis, and coronary Artery disease. N. Engl. J. Med. 2005, 352(16):1685-1695.
4. Calder P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br. J. Clin. Pharmacol. 2013, 75(3):645-662.
5. Endres S., Ghorbani R., Kelley V.E., Georgilis K., Lonnemann G., van der Meer J.W., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 1989, 320(5):265-271.
6. Lo C.J., Chiu K.C., Fu M., Lo R., Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J. Surg. Res. 1999, 82(2):216-221.
7. Kong W., Yen J.H., Vassiliou E., Adhikary S., Toscano M.G., Ganea D. Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family. Lipids health Dis. 2010, 9:12.
8. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142(5):687-698.
9. Calder P.C. Long chain fatty acids and gene expression in inflammation and immunity. Curr. Opin. Clin. Nutr. Metabolic care 2013, 16(4):425-433.
10. Bouwens M., van de Rest O., Dellschaft N., Bromhaar M.G., de Groot L.C., Geleijnse J.M., et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am. J. Clin. Nutr. 2009, 90(2):415-424.
11. Mozaffarian D., Wu J.H. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?. J. Nutr. 2012, 142(3):614s-625s.
12. Mori T.A., Bao D.Q., Burke V., Puddey I.B., Beilin L.J. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999, 34(2):253-260.
13. Mesa M.D., Buckley R., Minihane A.M., Yaqoob P. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein. Atherosclerosis 2004, 175(2):333-343.
14. Stanke-Labesque F., Moliere P., Bessard J., Laville M., Vericel E., Lagarde M. Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers. Br. J. Nutr. 2008, 100(4):829-833.
15. Mickleborough T.D., Tecklenburg S.L., Montgomery G.S., Lindley M.R. Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin. Nutr. (Edinburgh, Scotland) 2009, 28(1):71-77.
16. Corson M.A., Jones P.H., Davidson M.H. Review of the evidence for the clinical Utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am. J. Cardiol. 2008, 101(12, Suppl.):S41-S50.
17. Schaefer E.J., McNamara J.R., Asztalos B.F., Tayler T., Daly J.A., Gleason J.L., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol. 2005, 95(9):1025-1032.
18. Thongtang N., Ai M., Otokozawa S., Himbergen T.V., Asztalos B.F., Nakajima K., et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am. J. Cardiol. 2011, 107(3):387-392.
19. Stark K.D., Holub B.J. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am. J. Clin. Nutr. 2004, 79(5):765-773.
20. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article3.
21. Pfaffl M.W., Tichopad A., Prgomet C., Neuvians T.P. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-Excel-based tool using pair-wise correlations. Biotechnol. Lett. 2004, 26(6):509-515.
22. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004, 109(22):2705-2711.
23. Yates C.M., Calder P.C., Ed Rainger G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol. Ther. 2014, 141(3):272-282.
24. Rangel-Huerta O.D., Aguilera C.M., Mesa M.D., Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br. J. Nutr. 2012, 107(Suppl. 2):S159-S170.
25. Cazzola R., Russo-Volpe S., Miles E.A., Rees D., Banerjee T., Roynette C.E., et al. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 2007, 193(1):159-167.
26. Pot G.K., Brouwer I.A., Enneman A., Rijkers G.T., Kampman E., Geelen A. No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: a randomized controlled trial in healthy, middle-aged individuals. Eur. J. Clin. Nutr. 2009, 63(11):1353-1359.
27. Manson J.E., Bassuk S.S., Lee I.M., Cook N.R., Albert M.A., Gordon D., et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. trials 2012, 33(1):159-171.
28. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369(9567):1090-1098.
29. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011, 58(20):2047-2067.
30. Rees D., Miles E.A., Banerjee T., Wells S.J., Roynette C.E., Wahle K.W., et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am. J. Clin. Nutr. 2006, 83(2):331-342.
31. Rudkowska I., Paradis A.M., Thifault E., Julien P., Tchernof A., Couture P., et al. Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. J. Nutr. Biochem. 2013, 24(1):54-61.
32. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U S A. 1997, 94(9):4312-4317.
33. Botolin D., Wang Y., Christian B., Jump D.B. Docosahexaneoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. J. Lipid Res. 2006, 47(1):181-192.
34. Schulman I.G. Nuclear receptors as drug targets for metabolic disease. Adv. Drug Deliv. Rev. 2010, 62(13):1307-1315.
35. Anderson O.S., Sant K.E., Dolinoy D.C. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J. Nutr. Biochem. 2012, 23(8):853-859.
36. Wen A.Y., Sakamoto K.M., Miller L.S. The role of the transcription factor CREB in immune function. J. Immunol. (Baltimore, Md: 1950) 2010, 185(11):6413-6419.
37. Altarejos J.Y., Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat. Rev. Mol. Cell. Biol. 2011, 12(3):141-151.
38. Nizet V., Johnson R.S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 2009, 9(9):609-617.
39. Itariu B.K., Zeyda M., Hochbrugger E.E., Neuhofer A., Prager G., Schindler K., et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am. J. Clin. Nutr. 2012, 96(5):1137-1149.
40. Ha M.K., Song Y.H., Jeong S.J., Lee H.J., Jung J.H., Kim B., et al. Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biological Pharm. Bull. 2011, 34(9):1432-1437.
41. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9(11):798-809.
42. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science (New York, NY) 1999, 285(5425):248-251.
43. Wei W., Chen M., Zhu Y., Wang J., Zhu P., Li Y., et al. Down-regulation of vascular HMGB1 and RAGE expression by n-3 polyunsaturated fatty acids is accompanied by amelioration of chronic vasculopathy of small bowel allografts. J. Nutr. Biochem. 2012, 23(10):1333-1340.
44. Serhan C.N., Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 2008, 153(Suppl. 1):S200-S215.
45. Lanman R.B., Wolfert R.L., Fleming J.K., Jaffe A.S., Roberts W.L., Warnick G.R., et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev. Cardiol. 2006, 9(3):138-143.
46. Piccirillo C.A., Bjur E., Topisirovic I., Sonenberg N., Larsson O. Translational control of immune responses: from transcripts to translatomes. Nat. Immunol. 2014, 15(6):503-511.